Bioxytran IncOTCQB:BIXT
- LAST PRICE0.0920
- TODAY'S CHANGE (%)0.0060 (6.9767%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0860 / 0.0860
- Day Range
- 52 Week Range
- Volume58,300
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BIXT |
|---|---|---|
| 09:32 ET | 6400 | 0.086 |
| 09:34 ET | 5000 | 0.0824 |
| 11:27 ET | 2000 | 0.094 |
| 12:39 ET | 5000 | 0.0752 |
| 01:35 ET | 6147 | 0.086 |
| 01:37 ET | 3753 | 0.08 |
| 02:22 ET | 5000 | 0.0926 |
| 02:44 ET | 10000 | 0.092 |
| 02:49 ET | 10000 | 0.0935 |
| 03:16 ET | 5000 | 0.092 |
Jun 12, 2024
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now, from 7:00AM ET on Wednesday Jun 12, 2024 by Dow Jones
7:00AM ET on Wednesday Jun 12, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Bioxytran Inc | 16.1M | -3.1x | --- |
Neurosense Therapeutics Ltd | 16.2M | -1.2x | --- |
Sensei Biotherapeutics Inc | 16.5M | -0.5x | --- |
GlycoMimetics Inc | 16.6M | -0.4x | --- |
Microbot Medical Inc | 16.6M | -1.2x | --- |
CytoMed Therapeutics Ltd | 22.8M | -6.8x | --- |
Company Information
Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.
Contact Information
- Headquarters
- 75 2Nd Ave, Suite 605 Ste 605NEEDHAM, MA, United States 02494
- Phone
- 617-494-1199
- Fax
- ---
Executives
- Chairman of the Board, President, Chief Executive Officer
- David Platt
- Chief Financial Officer, Treasurer, Secretary
- Ola Soderquist
- Interim Chief Medical Officer
- Leslie Ajayi
- Chief Communications Officer
- Mike Sheikh
- Director
- Radka Milanova
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 175.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.69 |
EPS | $-0.03 |
Book Value | $-0.02 |
P/E Ratio | -3.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
